LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Assessed for Diagnosis of Norovirus Gastroenteritis

By LabMedica International staff writers
Posted on 14 Mar 2012
Print article
The sensitivity and specificity of a commercial Norovirus immunochromatographic test has been evaluated on human stool samples.

The immunochromatographic test is based on reverse transcription-polymerase chain reaction (RT-PCR) and the sensitive RT-nested PCR and was compared with another commercial real-time RT-PCR for detection of Norovirus in stool samples.

Scientists at Mahidol University (Bangkok, Thailand) tested 86 stool samples for noroviruses using the commercial immunochromatographic test RIDA QUICK Norovirus, which uses the biotin-streptavidin-peroxidase method. In addition, 54 Norovirus-positive samples from a second test group were also detected, and the copy number of Norovirus quantified by using a commercial real-time RT-PCR. Norovirus GI and GII antigens in stool samples can be detected using the RIDA QUICK Norovirus Test.

The sensitivity was analyzed using stool samples of the two test groups, which were confirmed for Norovirus infection by RT-PCR and RT-nested PCR, respectively. Based on the RT-PCR, the sensitivity of the RIDAQUICK Norovirus assay (R-Biopharm; Darmstadt, Germany) was 83.3% (15/18 samples), but compared with the RT-nested PCR, the sensitivity decreased to 48.2% (26/54 samples). The specificity of the assay was analyzed using Norovirus-negative stool samples from the control group and accounted for 87.5% (28/32 samples). The assay revealed false positives of 12.5%.

Among 23 stool samples showing Norovirus positive by both the RIDA QUICK Norovirus assay and the real-time RT-PCR (Shanghai ZJ Bio-Tech, Shanghai, China), the virus could be detected in samples taken on days 1–8 after onset of illness and these samples harbored Norovirus GII. The real-time RT-PCR for the simultaneous detection of Norovirus GI and GII and quantitation was completed on the LightCycler 1.5 Instrument Real Time PCR System (Roche Diagnostics, Mannheim, Germany). Viral ribonucleic acid (RNA) was extracted using the QIAam Viral RNA extraction kit (QIAGEN GmbH, Hilden, Germany).

The authors concluded that the RIDA QUICK Norovirus assay is rapid and simple to perform. The assay has high sensitivity and specificity. This method is appropriate to use for early diagnosis of acute gastroenteritis caused by noroviruses and for rapid screening of Norovirus infections in patients with acute gastroenteritis in both developed and developing countries where the RT-PCR method has not been established for routine diagnosis. However, negative results where Norovirus is strongly suspected should be further tested by more sensitive molecular techniques.

The study was published online on February 23, 2012, in the European Journal of Clinical Microbiology & Infectious Diseases.

Related Links:
Mahidol University
R-Biopharm
Roche Diagnostics



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.